Xencor (NASDAQ:XNCR – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Analyst Recommendations
This is a summary of current ratings and price targets for Xencor and ProKidney, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xencor | 1 | 3 | 6 | 1 | 2.64 |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
Xencor currently has a consensus price target of $42.22, indicating a potential upside of 13.84%. ProKidney has a consensus price target of $10.00, indicating a potential upside of 856.94%. Given ProKidney’s stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Xencor.
Profitability
This table compares Xencor and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xencor | -58.79% | -21.28% | -15.17% |
| ProKidney | -13,326.71% | N/A | -35.31% |
Insider and Institutional Ownership
51.6% of ProKidney shares are owned by institutional investors. 5.1% of Xencor shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Xencor and ProKidney”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xencor | $125.58 million | 22.16 | -$91.92 million | ($1.59) | -23.33 |
| ProKidney | $890,000.00 | 354.97 | -$68.99 million | ($0.55) | -1.90 |
ProKidney has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Xencor has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Summary
ProKidney beats Xencor on 10 of the 14 factors compared between the two stocks.
About Xencor
Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
